Preventing Mortality from Influenza

Primary Prevention Strategy: Annual Vaccination

The Centers for Disease Control and Prevention recommends annual influenza vaccination as the single most effective measure for preventing influenza-related mortality, particularly in high-risk populations, with vaccine effectiveness of 80% in preventing death among elderly nursing home residents and 42-47% reduction in all-cause mortality among community-dwelling elderly persons 1, 2, 3
Vaccination prevents 80% of deaths in nursing home residents, even when effectiveness against influenza illness itself is only 30-40% 1, 4
Vaccine effectiveness reaches 50-60% for preventing hospitalization or pneumonia in high-risk institutionalized elderly 1, 4
High vaccination rates can induce herd immunity and reduce outbreak risk in closed settings when vaccine and circulating strains are well-matched 5, 6
Vaccination reduces all-cause mortality by 42-47% after adjustment for confounders in community-dwelling elderly (≥65 years) 2, 3
Prevents 26-45% of hospitalizations for influenza and pneumonia in community-dwelling elderly (≥65 years) 1, 2
Effectiveness against death ranges from 30 to >150 deaths prevented per 100,000 persons aged >65 years during epidemics 6

The Centers for Disease Control and Prevention recommends vaccinating all persons ≥65 years of age, residents of nursing homes and chronic-care facilities, adults and children with chronic pulmonary or cardiovascular disorders, and adults and children with chronic metabolic diseases 7
Healthcare workers and close contacts of high-risk persons should also be vaccinated to protect high-risk persons 7

When vaccine and circulating viruses are well-matched, effectiveness is 70-90% against influenza illness in healthy adults (<65 years) 1, 3, 4
Reduces work absenteeism and healthcare resource utilization by 32-45% in healthy adults (<65 years) 3, 8
Hospitalization rates for children 0-4 years range from 100-500/100,000 population, with highest rates in infants 0-1 years 6, 2
Vaccine reduces influenza-associated otitis media by approximately 30% in children 8

Antiviral therapy is a key adjunct but NOT a substitute for vaccination, according to the Centers for Disease Control and Prevention 6, 2
Neuraminidase inhibitors (oseltamivir, zanamivir) can be used for treatment and prophylaxis in high-risk patients 9, 10

The Centers for Disease Control and Prevention recommends beginning vaccination in early October through mid-November, but continuing throughout the entire influenza season as long as vaccine supplies are available 5, 6
Influenza activity can persist through February, March, or later 11
Do not delay vaccination waiting for "perfect" timing—vaccine effectiveness remains >0 for at least 5-6 months despite waning immunity (7-11% per month) 11

Minor illnesses with or without fever do not contraindicate influenza vaccine, according to the Centers for Disease Control and Prevention 11
Only defer vaccination during acute febrile illness until symptoms abate 11
Recent viral infections without fever are NOT contraindications 11
Administer vaccine during hospitalizations or routine healthcare visits before influenza season to increase coverage rates 5, 6

The influenza vaccine prevents 30-70% of hospitalizations for pneumonia and influenza among elderly persons living outside nursing homes or chronic-care facilities, according to the Centers for Disease Control and Prevention 12, 13, 14
Among frail elderly residing in nursing homes, influenza vaccine is 50-60% effective in preventing hospitalization and pneumonia, as recommended by the Centers for Disease Control and Prevention 15, 12, 13, 16, 14
The vaccine demonstrates 80% effectiveness in preventing death in high-risk institutionalized populations, as reported by the Centers for Disease Control and Prevention 15, 16
The influenza vaccine reduces influenza-associated otitis media by approximately 30% in young children, preventing secondary complications that could lead to hospitalization, according to the American Academy of Pediatrics 17, 14

Effectiveness varies primarily based on the degree of similarity between vaccine strains and circulating viruses each season, as stated by the World Health Organization 15, 12, 16, 18
Well-matched seasons demonstrate significantly higher effectiveness compared to mismatched seasons, as evidenced by pediatric studies showing 93% efficacy in well-matched years versus negative efficacy in poorly matched years, according to the Centers for Disease Control and Prevention 17
Elderly persons and those with chronic diseases develop lower postvaccination antibody titers than healthy young adults, yet still derive substantial benefit in preventing severe complications and hospitalization, as reported by the National Institute on Aging 15, 12, 13, 16, 18

Administer vaccine during hospitalizations or routine healthcare visits before influenza season to maximize coverage rates rather than requiring special visits, as recommended by the Centers for Disease Control and Prevention 15